Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common share equivalents):


		Years Ended December 31,
		2023				2022				2021
Common stock warrants			5,864				13,760				13,760
Common stock options and restricted stock units			4,020,154				3,077,608				1,420,050
Employee stock purchase plan			41,862				34,588				2,045
Total			4,067,880				3,125,956				1,435,855

Summary of Net Loss Per Share

The following table summarizes our net loss per share (in thousands, except per share data):


		Years Ended December 31,
		2023				2022				2021
Numerator:
Net loss attributable to aTyr Pharma, Inc.		$	(50,389	)		$	(45,338	)		$	(33,768	)

Denominator:
Shares used in computing net loss per share, basic and diluted			53,606,488				28,419,569				19,080,878

Net loss per share - basic and diluted		$	(0.94	)		$	(1.60	)		$	(1.77	)